Document:

EX-10.1

 Exhibit 10.1 

FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT 

This FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT, dated as of May 13, 2013 (this “Agreement”), among TOKAI
PHARMACEUTICALS, INC., a Delaware corporation (the “Issuer”), and the investors in the Issuer named in Schedule I hereto (collectively, the “Investors”), amending and restating the Fourth Amended and Restated
Investor Rights Agreement, dated as of September 9, 2011, as amended (the “Fourth Amended and Restated Investor Rights Agreement”), among the Issuer and certain of the Investors. 

WHEREAS, the Issuer and certain of the Investors (the “Series E Investors”) have entered into a Series E Convertible
Preferred Stock Purchase Agreement, dated as of the date hereof (the “Purchase Agreement”), pursuant to which the Series E Investors shall purchase from the Issuer shares of the Issuer’s Series E Convertible Preferred Stock,
$0.001 par value per share (“Series E Preferred Stock”); 
 WHEREAS, the Issuer and certain Investors are parties to
the Fourth Amended and Restated Investor Rights Agreement and the Issuer and such Investors desire to amend and restate the Fourth Amended and Restated Investor Rights Agreement in order to take into account the issuance of the Series E Preferred
Stock, such amendment being a condition precedent to the execution, delivery and performance of the Purchase Agreement; 

WHEREAS, the execution of this Agreement is a condition to the closing of the transactions contemplated by the Purchase Agreement;
and 
 WHEREAS, as an inducement to the Series E Investors to consummate the transactions contemplated by the Purchase
Agreement, the Issuer has agreed to enter into this Agreement; and 
 NOW, THEREFORE, in consideration of the premises and of
the mutual covenants and agreements herein contained, the parties hereto, intending to be legally bound, hereby agree as follows: 

1. Definitions. For purposes of this Agreement, the following terms have the following respective meanings: 

“Additional Shares” means shares of Common Stock (i) acquired by the Investors or (ii) issued or
issuable to the Investors upon conversion or exercise of any security of the Issuer other than by conversion of the Preferred Shares, provided that (a) in the case of clause (i) such shares of Common Stock are, at the time of their
acquisition, “restricted securities” as such term is defined in Rule 144 or otherwise subject to the restrictions on resale of Rule 144 and (b) in the case of clause (ii), such security is a “restricted security” at the time
of acquisition or is otherwise subject to restrictions on resale under Rule 144. 
 “Affiliate” means, with
respect to a particular person or entity, persons or entities controlling, controlled by or under common control with that person or entity, as well as any officers, directors and majority-owned entities of that person or entity and of its other
Affiliates and, with respect to any Investor that is part of the Satter Family, as defined in the Stockholders Agreement, any other member of the Satter Family. The term “control” (including, with correlative meanings, the terms
“controlled by” and “under common control with”), as applied to any person, means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such person, whether through
the ownership of voting securities or other ownership interest, by contract or otherwise. 
 “Agreement”
shall have the meaning given it in the first paragraph of this Agreement. 

 “Certificate of Incorporation” means the Issuer’s Seventh
Amended and Restated Certificate of Incorporation, as it may be amended or restated from time to time. 
 “Common
Stock” means the Common Stock, $0.001 par value per share, of the Issuer. 
 “Company Sale” means a
Deemed Liquidation Event (as such term is defined in the Certificate of Incorporation). 
 “Confidential
Information” means any information that is labeled as confidential, proprietary or secret that an Investor obtains from the Issuer pursuant to financial statements, reports and other materials provided by the Issuer to such Investor
pursuant to this Agreement or pursuant to visitation or inspection rights granted hereunder. 
 “Conversion
Shares” means the shares of Common Stock issued or issuable upon conversion of the Preferred Shares. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor federal statute, and
the rules and regulations thereunder that shall be in effect at the time. Any reference to a particular section thereof shall include a reference to the corresponding section, if any, of any such successor federal statute, and the rules and
regulations thereunder. 
 “FINRA” means the Financial Industry Regulatory Authority. 

“GAAP” means United States generally accepted accounting principles. 

“Holder” means any holder of Registrable Securities or Preferred Shares, including a Holder that has received
Registrable Securities pursuant to Section 4.3. 
 “Investor” shall have the meaning given it in the
first paragraph of this Agreement. 
 “Issuer” shall have the meaning given it in the first paragraph of
this Agreement. 
 “Material Adverse Effect” means any material adverse effect on the business, assets,
properties or financial condition of the Issuer. 
 “Person” means any natural person, firm, partnership,
association, corporation, company, trust, business trust, governmental entity or other entity. 
 “Preferred
Shares” mean any shares of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and Series E Preferred Stock. 

“Prospectus” means the prospectus included in any Registration Statement (including, without limitation, a
prospectus that discloses information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by such Registration Statement and all other amendments and supplements to the prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be
incorporated by reference in such prospectus. 
 “Purchase Agreement” shall have the meaning given it in the
first recital hereof. 

  
 - 2 - 

 “Qualified Public Offering” means a Qualified Public Offering as
such term is defined in Article FOURTH, Part C, Subsection 5.1 of the Certificate of Incorporation. 
 “Registrable
Securities” means (a) the Shares, (b) the Additional Shares, (c) any securities issued or issuable with respect to any Shares or Additional Shares referred to in the foregoing clauses (a) and (b), (i) upon any
conversion or exchange thereof, (ii) by way of stock dividend or other distribution, stock split or reverse stock split, or (iii) in connection with a combination of shares, recapitalization, merger, consolidation, exchange offer or other
reorganization. As to any particular Registrable Securities, once issued such securities shall cease to be Registrable Securities when (A) a Registration Statement with respect to the sale of such securities shall have become effective under
the Securities Act and such securities shall have been disposed of in accordance with such Registration Statement, (B) such securities shall have been distributed to a third party in reliance upon Rule 144, (C) subject to the provisions of
Section 4.1(b)(ii), such securities shall have been otherwise transferred, new certificates for such securities not bearing a legend restricting further transfer shall have been delivered by the Issuer and subsequent disposition of such
securities shall not require registration or qualification of such securities under the Securities Act or any similar state law then in force, (D) such securities shall have been acquired by the Issuer, (E) at such time, following a
Qualified Public Offering, as such securities become eligible for sale by the Holder thereof without being subject to notice requirements or volume or manner of sale limitations pursuant to Rule 144 under the Securities Act or (F) upon any
transfer in any manner to a person or entity that is not entitled, pursuant to Section 4.3, to the rights under this Agreement. In determining the number of Registrable Securities outstanding at any time or whether the Holders of the requisite
number of Registrable Securities have taken any action hereunder and in calculating the number of Registrable Securities for all purposes under this Agreement, (i) the Preferred Shares shall be deemed to have been converted at the then existing
conversion price and (ii) such calculation shall include the number of shares of Common Stock then deliverable upon conversion of the Preferred Shares. 

“Registration Expenses” means all fees and expenses incident to the performance of or compliance with the
provisions of Section 2 of this Agreement, whether or not any registration statement is filed or becomes effective, including, without limitation, all (i) registration and filing fees (including, without limitation, (A) fees with
respect to filings required to be made with FINRA in connection with an underwritten offering, (B) fees and expenses of compliance with state securities or blue sky laws (including, without limitation, fees and disbursements of counsel for the
underwriter or underwriters in connection with blue sky qualifications of the Registrable Securities and determination of the eligibility of the Registrable Securities for investment under the laws of such jurisdictions as provided in
Section 2.3(e)), and (C) fees and other expenses associated with the listing of the Shares and any Additional Shares on a registered national securities exchange), (ii) printing expenses (including, without limitation, expenses of
printing certificates for Registrable Securities and of printing Prospectuses), (iii) fees and disbursements of all independent registered public accounting firms referred to in Section 2.3 (including, without limitation, the reasonable
expenses of any special audit and “cold comfort” letters required by or incident to such performance), (iv) the fees and expenses of any “qualified independent underwriter” or other independent appraiser participating in an
offering pursuant to Rule 2720 of the FINRA Rules of Conduct, (v) fees and expenses of all attorneys, advisers, appraisers and other persons retained by the Issuer or any Subsidiary of the Issuer, (vi) the expenses relating to printing and
distributing all registration statements, underwriting agreements, securities sales agreements, indentures and any other documents necessary in order to comply with this Agreement and (vii) the reasonable out-of-pocket expenses of the Holders
of the Registrable Securities being registered in such registration incurred in connection therewith including, without limitation, the reasonable fees and disbursements of not more than one counsel chosen by the Holders of a majority of the
then-outstanding Registrable Securities to be included in such Registration Statement; provided, however, that if a registration under Section 2.1 is withdrawn at the request of the Investors requesting such registration (other
than, prior to the end of the applicable 

  
 - 3 - 

 
period specified in Section 2.3(b), as a result of information concerning a Material Adverse Effect that is made known to the Investors after the date on which such registration was
requested and if the requesting Investors elect not to have such registration counted as a registration requested under Section 2.1) the Investors shall pay the Registration Expenses of such registration pro rata in accordance with the number
of their Registrable Securities that would otherwise have been included in such registration. “Registration Expenses” shall not include any underwriting discounts or commissions or any transfer taxes payable in respect of the sale of
Registrable Securities by the Holders thereof. 
 “Registration Statement” means any registration statement
of the Issuer that covers any of the Registrable Securities pursuant to the provisions of this Agreement, and all amendments and supplements to any such registration statement, including post-effective amendments, in each case including the
Prospectus, and all exhibits and all material incorporated by reference or deemed to be incorporated by reference in such registration statement (other than a registration statement on Form S-8 or Form S-4, or their successors, or any other form for
a similar limited purpose, or any registration statement covering only securities proposed to be issued in exchange for securities or assets of another corporation). 

“Rule 144” means Rule 144 (or any successor provision) under the Securities Act. 

“Rule 145” means Rule 145 (or any successor provision) under the Securities Act. 

“SEC” means the Securities and Exchange Commission or any other federal agency at the time administering the
Securities Act or the Exchange Act. 
 “Securities Act” means the Securities Act of 1933, as amended, or any
successor federal statute, and the rules and regulations thereunder that shall be in effect at the time. Any reference to a particular section thereof shall include a reference to the corresponding section, if any, of any such successor federal
statute, and the rules and regulations thereunder. 
 “Senior Preferred Designee” means a Senior Preferred
Designee as such term is defined in Section 1(a)(iii) of the Stockholders Agreement. 
 “Senior Preferred
Stock” means the Series C Preferred Stock, the Series D Preferred Stock and the Series E Preferred Stock. 

“Senior Registrable Securities” means shares of Common Stock issued or issuable upon conversion of the Senior
Preferred Stock that are Registrable Securities. 
 “Senior Required Securities” means shares representing a
majority of the Senior Preferred Stock (voting as a single class in accordance with Article FOURTH, Part C, Subsection 3.1 of the Certificate of Incorporation) or, following the automatic conversion of each series of Preferred Stock under
Section 5.1 of the Certificate of Incorporation, the shares of Common Stock issued upon conversion of the Senior Preferred Stock (voting as a single class based upon the number of votes to which each such share was entitled prior to such
conversion into Common Stock). 
 “Series A Preferred Stock” means the Series A Convertible Preferred Stock,
$0.001 par value per share, of the Issuer. 
 “Series B-1 Preferred Stock” means the Series B-1 Convertible
Preferred Stock, $0.001 par value per share, of the Issuer. 

  
 - 4 - 

 “Series B-2 Preferred Stock” means the Series B-2 Convertible
Preferred Stock, $0.001 par value per share, of the Issuer. 
 “Series C Preferred Stock” means the Series C
Convertible Preferred Stock, $0.001 par value per share, of the Issuer. 
 “Series D Preferred Stock” means
the Series D-1 Preferred Stock, the Series D-2 Preferred Stock and the Series D-3 Preferred Stock. 
 “Series D-1
Preferred Stock” means the Series D-1 Convertible Preferred Stock, $0.001 par value per share, of the Issuer. 

“Series D-2 Preferred Stock” means the Series D-2 Convertible Preferred Stock, $0.001 par value per share, of
the Issuer. 
 “Series D-3 Preferred Stock” means the Series D-3 Convertible Preferred Stock, $0.001 par
value per share, of the Issuer. 
 “Series E Preferred Stock” has the meaning given it in the first recital
hereof. 
 “Shares” means the Conversion Shares. 

“Significant Holder” means any Holder holding at least 8,000,000 Preferred Shares (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Shares). 

“Special Registration” means the registration of shares of equity securities and/or options or other rights in
respect thereof to be offered solely to directors, members of management, employees, consultants or sales agents, distributors or similar representatives of the Issuer or its direct or indirect Subsidiaries, solely on Form S-8 or Form S-4 or any
successor form. 
 “Stockholders Agreement” means the Fifth Amended and Restated Stockholders Agreement by
and among the Issuer, the Investors and the Common Stockholders named therein, dated as of the date hereof, as amended from time to time. 

“Subsidiary” means, with respect to any Person, any other Person, a majority of the outstanding voting stock
or other equity interests of which is owned, directly or indirectly, by that Person. 
 “underwritten
registration” or “underwritten offering” means a registration in which securities of the Issuer (including Registrable Securities) are sold to an underwriter for re-offering to the public. 

2. Registration. 

2.1 Demand Registration. 

(a) Requests. Subject to the provisions of Section 2.7, at any time or from time to time after the earlier of
(i) the four year anniversary of the date hereof or (ii) 180 days following the effective date of the initial public offering of the Common Stock, a Holder or the Holders of (x) at least seventy-five percent (75%) of the combined
voting power of the issued and outstanding Senior Preferred Stock (voting as a single class in accordance with Article FOURTH, Part C, Subsection 3.1 of 

  
 - 5 - 

 
the Certificate of Incorporation) in the case of clause (i) of this sentence or (y) the Senior Required Securities in the case of clause (ii) of this sentence shall have the right
to make written requests that the Issuer effect a registration under the Securities Act with respect to at least 20% of the outstanding Registrable Securities, or any lesser percentage of the outstanding Registrable Securities if the reasonably
anticipated aggregate offering price to the public would exceed $10,000,000; provided, however, in the event that Novartis (as defined in the Stockholders Agreement) or any of its Affiliates holding Senior Preferred Stock is determined by the Board
of Directors of the Issuer to not be a Financial Fund (as defined in the Stockholders Agreement), such Holder shall not be entitled to request registration under this Section 2.1(a) and the percentage of Senior Preferred Stock required to
request registration under this Section 2.1(a) shall be reduced by the percentage of Senior Preferred Stock held by such Holder. Such requests shall specify the intended method of disposition thereof by such Holder, including whether the
registration requested is for an underwritten offering. The Issuer shall not be required to effect a registration pursuant to this Section 2.l(a) on more than two occasions during the term of this Agreement provided, however, that if the Issuer
is not entitled to use Commission Form S-3 due to the Issuer’s failure to comply with its filing obligations under the Exchange Act, the Holders shall be entitled to additional S-1 Registrations under Section 2.1(a) notwithstanding the
foregoing limitation; except that in no event shall the Issuer be required to effect any registration on more than one occasion during any 12-month period. Nothing in this Agreement shall prevent any Holder from making a request under
Section 2.1(a) or 2.1(b) prior to converting the Preferred Shares. The Issuer shall not be required to file any Registration Statement pursuant to this Section 2.1(a) if at the time of any request to register Registrable Securities
pursuant to this Section 2.1(a), the Issuer furnishes to the requesting Holder or Holders a certificate signed by the Chief Executive Officer (or, if none, the President) of the Issuer stating that the Issuer has a good faith intent to engage
in a firmly underwritten public offering within 90 days of such request, such right to delay a request to be exercised by the Issuer not more than once in any twelve- month period. 

(b) Form S-3 Registration. If at any time the Issuer is eligible to file a Registration Statement under the Securities
Act on Form S-3 (or any successor short form registration statement), a Holder or Holders of the Senior Required Securities shall have the right to make written requests that the Issuer effect a registration under the Securities Act on Form S-3 of
all or part of the Registrable Securities of the Holder making such request, which requests shall specify the intended method of disposition thereof by such Holder, including whether (i) the registration requested is for an underwritten
offering and (ii) the Registration Statement covering such Registrable Securities shall provide for the sale by the Holder thereof of the Registrable Securities from time to time on a delayed or a continuous basis under Rule 415 under the
Securities Act; provided, however, in the event that Novartis or any of its Affiliates holding Senior Preferred Stock is determined by the Board of Directors of the Issuer to not be a Financial Fund, such Holder shall not be entitled to request
registration under this Section 2.1(b) and the percentage of Senior Preferred Stock required to request registration under this Section 2.1(b) shall be reduced by the percentage of Senior Preferred Stock held by such Holder. The Issuer
shall not be required to file any such Registration Statement (i) if the reasonably anticipated aggregate price to the public of the offering would not exceed $7,500,000 (unless the request is for all remaining Registrable Securities) or
(ii) if at the time of any request to register Registrable Securities pursuant to this Section 2.1(b), the Issuer furnishes to the requesting Holder or Holders a certificate signed by the Chief Executive Officer (or, if none, the
President) of the Issuer stating that the Issuer has a good faith intent to engage in a firmly underwritten public offering within 90 days of such request, such right to delay a request to be exercised by the Issuer not more than once in any
twelve-month period. No requested registration under this Section 2.1(b) shall constitute a “demand” registration for purposes of Section 2.1(a). So long as the provisions and requirements of this Section 2.l(b) are
satisfied and subject to the other provisions of this Agreement, there shall be no limit on the number of times a Holder or Holders may make a written request that the Issuer effect a registration hereunder except that the Issuer

  
 - 6 - 

 
shall not be required to effect a registration pursuant to this Section 2.l(b) on more than two occasions during any 12-month period. 

(c) Obligation to Effect Registration. Within 20 days after receipt by the Issuer of any request for registration
pursuant to Section 2.1(a) or 2.1(b), the Issuer shall promptly give written notice of such requested registration to all Holders, and thereupon will use its best efforts to effect the registration under the Securities Act of: 

(i) the Registrable Securities that the Issuer has been so requested to register pursuant to Section 2.1(a) or 2.1(b),
and 
 (ii) all other Registrable Securities that the Issuer has been requested to register by the Holders thereof by
written request given to the Issuer within 10 days after the Issuer has given such written notice (which request shall specify the intended method of disposition of such Registrable Securities), all to the extent required to permit the disposition
(in accordance with the intended methods thereof as aforesaid) of the Registrable Securities so to be registered. 
 (d)
Effective Registration Statement. A registration requested pursuant to Section 2.1(a) or 2.1(b) shall not be deemed to have been effected unless the Registration Statement for such registration is declared effective by the SEC and
remains effective for the period specified in Section 2.3(b). Notwithstanding the preceding sentence, a registration requested pursuant to Section 2.1(a) or 2.1(b) that does not become effective after the Issuer has filed a Registration
Statement with respect thereto by reason of the refusal to proceed of the Holders of Registrable Securities requesting the registration, or by reason of a request by the Holders of (x) at least seventy-five percent (75%) of the combined
voting power of the issued and outstanding Senior Preferred Stock (voting as a single class in accordance with Article FOURTH, Part C, Subsection 3.1 of the Certificate of Incorporation) in the case of a registration requested pursuant to
Section 2.1(a)(i) or (y) the Senior Required Securities in the case of a registration requested pursuant to Section 2.1(a)(ii) for which registration is being requested that such registration be withdrawn, shall be deemed to have been
effected by the Issuer at the request of such Holders. 
 (e) Pro Rata Allocation. If the Holders of (x) at least
seventy-five percent (75%) of the combined voting power of the issued and outstanding Senior Preferred Stock (voting as a single class in accordance with Article FOURTH, Part C, Subsection 3.1 of the Certificate of Incorporation) in the case of
a registration requested pursuant to Section 2.1(a)(i) or (y) the Senior Required Securities in the case of a registration requested pursuant to Section 2.1(a)(ii) or 2.1(b) determine, based on consultation with the managing
underwriters or, in an offering that is not underwritten, with an investment banker, that the number of securities to be sold in any such offering should be limited due to market conditions or otherwise, Holders of Registrable Securities proposing
to sell their securities in such registration shall be entitled to include in such registration: 
 (i) first, all Senior
Registrable Securities requested to be included by the Holders, allocated pro rata based on the number of Senior Registrable Securities as to which registration was requested by such Holders; 

(ii) second, to the extent that the number of shares registered pursuant to clause (i) above is less than the number of
securities to be sold in such offering, the remaining Registrable Securities requested to be included by the Holders, pro rata based on the number of such Registrable Securities as to which registration was requested by such Holders. 

  
 - 7 - 

 (f) Inclusion of Other Securities in Demand Registration. 

(i) The Issuer may, subject to the remainder of this Section 2.l(f), elect to include in any Registration Statement made
pursuant to Section 2.1(a) or 2.1(b), authorized but unissued shares of Common Stock, or shares of Common Stock held as treasury stock, provided, however that in the event that (i) such Registration Statement was made
pursuant to Section 2.1(a), (ii) the Issuer elects to include such shares of Common Stock in such Registration Statement and (iii) the number of shares requested pursuant to Section 2.1(a) is reduced pursuant to
Section 2.1(f)(ii), then the registration made with regard to such Registration Statement will not be deemed to be one of the two allowable registration requests permitted to be made pursuant to Section 2.1(a). 

(ii) If any Registration Statement made pursuant to Section 2.1(a) or 2.1(b) involves an underwritten offering and the
managing underwriter of such offering (or, in connection with an offering that is not underwritten, an investment banker) shall advise the Issuer that the number of securities requested to be included in such registration exceeds the largest number
that can be sold in an orderly manner in such offering within a price range acceptable to the selling Holders, the Issuer shall include in such registration: 

(A) first, all shares of Common Stock requested to be included in such registration by the selling Holders subject to
Section 2.1(e); 
 (B) second, to the extent that the number of securities to be registered pursuant to clause
(A) above is less than the largest number that can be sold in an orderly manner in such offering within a price range acceptable to the selling Holders, securities that the Issuer proposes to register; and 

(C) third, to the extent that the number of shares registered pursuant to clauses (A) and (B) above is less than the
largest number that can be sold in an orderly manner in such offering within a price range acceptable to the selling Holders, the securities requested to be included by any other holders. 

The securities to be included in any such registration pursuant to clause (C) shall be allocated on a pro rata basis among all holders
requesting that securities be included in such registration pursuant to such clause on the basis of the number of securities requested to be included by such holders. 

2.2 Piggyback Registration. If the Issuer at any time proposes to register any Common Stock under the Securities Act
(other than pursuant to a Registration Statement relating solely to the sale of securities on Form S-4 with respect to any merger, consolidation or acquisition, pursuant to Section 2.1 or pursuant to a Special Registration), whether or not for
sale for its own account, and the registration form to be used may be used for the registration of Registrable Securities, it shall give prompt written notice to all Holders of its intention to do so and, upon the written request of any Holder given
to the Issuer within 10 days after the Issuer has given any such notice (which request shall specify the Registrable Securities intended to be disposed of by such Holder and the intended method of disposition thereof), the Issuer will use its best
efforts to effect the registration under the Securities Act of all Registrable Securities that the Issuer has been so requested to register by the Holders thereof, to the extent required to permit the disposition (in accordance with the intended
methods thereof as aforesaid) of the Registrable Securities so to be registered, provided that: 

  
 - 8 - 

 (a) if, at any time after giving written notice of its intention to register any
Common Stock and prior to the effective date of the Registration Statement filed in connection with such registration, the Issuer shall determine for any reason not to register such Common Stock, the Issuer may, at its election, give written notice
of such determination to each Holder that was previously notified of such registration and, thereupon, shall not register any Registrable Securities in connection with such registration (but shall nevertheless pay the Registration Expenses in
connection therewith), without prejudice, however, to the rights of any Holders to request that a registration be effected under Section 2.1; and 

(b) if the Issuer shall be advised in writing by the managing underwriters (or, in connection with an offering that is not
underwritten, by an investment banker) that due to marketing factors, the number of securities requested to be included in such registration exceeds the number of such securities that can be sold in such offering in an orderly manner within a price
range that is acceptable to the Issuer, the Issuer shall include in such registration: 
 (i) first, all shares of Common
Stock that the Issuer proposes to register for its own account or the account of the holder or holders initially requesting or demanding such registration; 

(ii) second, to the extent that the number of shares registered pursuant to clause (i) above is less than the largest
number that can be sold in an orderly manner in such offering within a price range acceptable to the Issuer, the Registrable Securities requested to be included by the Holders subject to Section 2.1(e); 

(iii) third, to the extent that the number of shares registered pursuant to clauses (i) and (ii) above is less than
the largest number that can be sold in an orderly manner in such offering within a price range acceptable to the Issuer, the securities requested to be included by any other holders, 

and the Issuer shall so provide in any registration agreement hereinafter entered into with respect to any of its securities. 

The securities to be included in any such registration pursuant to clause (ii) or (iii) shall be allocated on a pro rata basis among all holders
requesting that securities be included in such registration pursuant to such clause on the basis of the number of securities requested to be included by such holders (in the case of clause (ii), subject to Section 2.1(e)). 

Subject to Section 2.5, no registration effected under this Section 2.2 shall relieve the Issuer from its obligation to effect
registrations upon request under Section 2.1. Nothing in this Agreement shall prevent any Holder from making a request under this Section 2.2 prior to converting the Preferred Shares. 

2.3 Registration Procedures. If and whenever the Issuer is required to use its best efforts to effect the registration
of any Registrable Securities under the Securities Act as provided in Sections 2.1 and 2.2, the Issuer shall: 
 (a) prepare
and file with the SEC, as soon as practicable, a Registration Statement with respect to such securities, make all required filings with FINRA and use its best efforts to cause such Registration Statement to become effective at the earliest possible
date; 
 (b) prepare and file with the SEC such amendments and supplements to such Registration Statement and the Prospectus
used in connection therewith and such other documents as may 

  
 - 9 - 

 
be necessary to keep such Registration Statement effective until the earlier of (i) 30 days after the effective date of such Registration Statement (360 days in the case of a shelf
registration pursuant to Section 2.1 (b)) or (ii) the consummation of the disposition by the Holders of all the Registrable Securities covered by such Registration Statement, and otherwise comply with the provisions of the Securities
Act with respect to the disposition of all securities covered by such Registration Statement; 
 (c) furnish to counsel (if
any) selected by the Holders of a majority of the Registrable Securities covered by such Registration Statement and to counsel for the underwriters in any underwritten offering copies of all documents proposed to be filed with the SEC in connection
with such registration a reasonable time prior to the proposed filing thereof and give reasonable consideration in good faith to any comments of such Holders, counsel and underwriters; 

(d) furnish to each seller of Registrable Securities, without charge, such reasonable number of conformed copies of such
Registration Statement and of each such amendment and supplement thereto (in each case, including all exhibits (including exhibits incorporated by reference), financial statements, schedules and all documents incorporated therein, deemed to be
incorporated therein by reference or filed therewith, except that the Issuer shall not be obligated to furnish any seller of securities with more than two copies of such exhibits and documents), such number of copies of the Prospectus included in
such Registration Statement (including each preliminary prospectus and any summary prospectus) in conformity with the requirements of the Securities Act, and such other documents, as such seller may reasonably request in order to facilitate the
disposition of the securities owned by such seller; 
 (e) use its best efforts to register or qualify and cooperate with the
Holders of Registrable Securities, the underwriters and their respective counsels in connection with the registration or qualification (or exemption from such registration or qualification) of the securities covered by such Registration Statement
under such other securities or blue sky laws of such jurisdictions as each seller shall request; provided, that where Registrable Securities are offered other than through an underwritten offering, the Issuer agrees to cause its counsel to
perform blue sky investigations and file registrations and qualifications required to be filed pursuant to this Section 2.3(e)); keep each such registration or qualification (or exemption therefrom) effective during the period such Registration
Statement is required to be effective hereunder and do any and all other acts and things that may be necessary or advisable to enable such seller to consummate the disposition in such jurisdictions of the securities owned by such seller;
provided, however, that the Issuer shall not be required in connection with this paragraph (e) to qualify as a foreign corporation or to execute a general consent to service of process in any jurisdiction or to amend its
Certificate of Incorporation or Bylaws in a manner that the Board of Directors of the Issuer determines is inadvisable; 

(f) (i) notify each Holder of Registrable Securities subject to such Registration Statement if such Registration Statement, at
the time it or any amendment thereto became effective, (x) contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading upon
discovery by the Issuer of such material misstatement or omission or (y) upon discovery by the Issuer of the happening of any event as a result of which the Issuer believes there would be such a material misstatement or omission, and, as
promptly as practicable, prepare and file with the SEC a post-effective amendment to such Registration Statement and use best efforts to cause such post-effective amendment to become effective such that such Registration Statement, as so amended,
shall not contain an untrue 

  
 - 10 - 

 
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and (ii) notify each Holder of
Registrable Securities subject to such Registration Statement, at any time when a Prospectus relating thereto is required to be delivered under the Securities Act, if the Prospectus included in such Registration Statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading upon discovery by
the Issuer of such material misstatement or omission or upon discovery by the Issuer of the happening of any event as a result of which the Issuer believes there would be such a material misstatement or omission, and, as promptly as is practicable,
prepare and furnish to such Holder a reasonable number of copies of a supplement to or an amendment of such Prospectus as may be necessary so that, as thereafter delivered to the purchasers of such securities, such Prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading and each such Holder of
Registrable Securities shall immediately discontinue any sales of Registrable Securities pursuant to such Registration Statement until such Holder of Registrable Securities has received copies of a supplemented or amended Prospectus or until such
Holder of Registrable Securities is advised in writing by the Issuer that the then current Prospectus may be used and has received copies of any additional or supplemental filings that are incorporated or deemed incorporated by reference in such
Prospectus; 
 (g) otherwise use its best efforts to comply with all applicable rules and regulations of the SEC, and make
available to its security holders, as soon as reasonably practicable, an earnings statement of the Issuer complying with the provisions of Section 11(a) of the Securities Act and Rule 158 promulgated under the Securities Act (or any similar
rule promulgated under the Securities Act) no later than 45 days after the end of any 12-month period (or 90 days after the end of any 12-month period if such period is a fiscal year) (i) commencing at the end of any fiscal quarter in which
Registrable Securities are sold to an underwriter or to underwriters in a firm commitment or best efforts underwritten offering and (ii) if not sold to an underwriter or to underwriters in such an offering, commencing on the first day of the
first fiscal quarter of the Issuer after the effective date of the relevant Registration Statement, which statements shall cover said 12-month periods; 

(h) promptly notify each Holder of any Registrable Securities covered by such Registration Statement, their counsel and the
underwriters (i) when such Registration Statement, or any post-effective amendment to such Registration Statement, shall have become effective, or any amendment of or supplement to the Prospectus used in connection therewith shall have been
filed, (ii) of any request by the SEC to amend such Registration Statement or to amend or supplement such Prospectus or for additional information, (iii) of the issuance by the SEC of any stop order suspending the effectiveness of such
Registration Statement or of any order preventing or suspending the use of any preliminary prospectus or the initiation or threatening of any proceedings for any of such purposes, (iv) of the suspension of the qualification of such securities
for offering or sale in any jurisdiction, or of the institution of any proceedings for any of such purposes and (v) if at any time when a Prospectus is to be required by the Securities Act to be delivered in connection with the sale of the
Registrable Securities, the representations and warranties of the Issuer contained in any agreement (including the underwriting agreement contemplated in Section 2.4(b) below), to the knowledge of the Issuer, cease to be true and correct in any
material respect; 
 (i) use its best efforts to prevent the issuance of any order suspending the effectiveness of the
Registration Statement or of any order preventing or suspending the use of a Prospectus or suspending the qualification (or exemption from qualification) of any of the Registrable Securities covered thereby for sale in any jurisdiction, and, if any
such order is issued, to use its best efforts to obtain the withdrawal of any such order at the earliest possible moment; 

(j) prior to the effective date of the Registration Statement, (i) provide the registrar or transfer agent for the Common
Stock or such other Registrable Securities with printed 

  
 - 11 - 

 
certificates for such securities in a form eligible for deposit with DTC and (ii) provide a CUSIP number for such securities; 

(k) have the right, if the Board of Directors of the Issuer, in its good faith judgment, determines that any registration of
Registrable Securities should not be made or continued because (x) it would materially interfere with any material financing, acquisition, corporation reorganization, merger, or other transaction involving the Issuer or any of its Subsidiaries
or (y) it would require the disclosure of material nonpublic information, which disclosure would have a Material Adverse Effect (each a “Valid Business Reason”), (i) to postpone filing a Registration Statement until such
Valid Business Reason no longer exists, but in no event for more than 60 days, and (ii) to cause any Registration Statement that has already been filed to be withdrawn and its effectiveness terminated or to postpone amending or supplementing
such Registration Statement until such Valid Business Reason no longer exists, but in no event for more than 60 days (the “Postponement Period”); provided, however, that in no event shall the Issuer be permitted to
postpone or withdraw a Registration Statement under this subsection (k) or otherwise within 60 days after the expiration of the Postponement Period; 

(l) participate in marketing any Registrable Securities in connection with the registration of such securities under this
Agreement (including, but not limited to, making available reasonably necessary personnel and participating in a road show) as would be customary for public offerings of this nature; and 

(m) have the right, by furnishing to the requesting Holder or Holders a certificate signed by the Chief Executive Officer (or,
if none, the President) of the Issuer stating that, in the good faith judgment of the Board of Directors of the Issuer, circumstances exist (other than the circumstances set forth in subparagraph (k)), such that it would be detrimental to the Issuer
and its investors for a registration requested pursuant to Section 2.1 to be effected at such time, to direct that such request be delayed for a period not in excess of 180 days from the receipt of the request, such right to delay a request to
be exercised by the Issuer not more than once in any twelve-month period (and not within 60 days of any Postponement Period). 
 The Issuer
may require each Holder of any Registrable Securities as to which any registration is being effected to furnish to the Issuer such information regarding such Holder and the distribution of such securities as the Issuer may from time to time
reasonably request in writing and as shall be required by law in connection therewith. Each such Holder agrees to furnish promptly to the Issuer all information required to be disclosed in order to make the information previously furnished to the
Issuer by such Holder not materially misleading. 
 By the acquisition of Registrable Securities, each Holder shall be deemed to have agreed
that upon receipt of any notice from the Issuer pursuant to Section 2.3(f) or (k), such Holder will promptly discontinue such Holder’s disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable
Securities until such Holder shall have received, in the case of clause (i) of Section 2.3(f), notice from the Issuer that such Registration Statement has been amended, as contemplated by Section 2.3(f), or in the case of clause
(ii) of Section 2.3(f), copies of the supplemented or amended Prospectus contemplated by Section 2.3(f); or, in the case of Section 2.3(k), until the time period specified has elapsed or such Holder has received notice from the
Issuer that the Postponement Period has been terminated. If so directed by the Issuer, each Holder will deliver to the Issuer (at the Issuer’s expense) all copies, other than permanent file copies, in such Holder’s possession of the
Prospectus covering such Registrable Securities at the time of receipt of such notice. In the event that the Issuer shall 

  
 - 12 - 

 
give any such notice, the period mentioned in Section 2.3(b) shall be extended by the number of days during the period from and including the date of the giving of such notice to and
including the date when the Issuer shall have sent to the Holder copies of the supplemented or amended Prospectus contemplated by Section 2.3(f). 

2.4 Underwritten Offerings. The provisions of this Section 2.4 do not establish registration rights in addition to
those set forth in Sections 2.1, 2.2 and 2.3, but instead set forth procedures applicable, in addition to those set forth in Sections 2.1 through 2.3, to any registration that is an underwritten offering. 

(a) Underwritten Offerings Exclusive. Whenever a registration requested pursuant to Section 2.1 or 2.2 is for an
underwritten offering, only securities that are to be distributed by the underwriters may be included in the registration. 

(b) Underwriting Agreement. If requested by the underwriters for any underwritten offering by Holders pursuant to a
registration requested under Section 2.1, the Issuer shall enter into an underwriting agreement with such underwriters for such offering, such agreement to be reasonably satisfactory in substance and form to the Issuer and to the underwriters
and to contain such representations and warranties by the Issuer and such other terms and provisions as are customarily contained in agreements of this type, including, but not limited to, indemnities to the effect and to the extent provided in
Section 2.8, provisions for the delivery of officers’ certificates, opinions of counsel and accountants’ “cold comfort” letters, and lock-up arrangements. The Holders of Registrable Securities to be distributed by such
underwriters shall be parties to such underwriting agreement. 
 (c) Selection of Underwriters. Whenever a registration is
for an underwritten offering, the Issuer shall have the right to select one or more underwriters to administer the offering; provided that the lead underwriter shall be an underwriter of nationally recognized standing. 

2.5 Lock-Up Agreements. If and whenever the Issuer proposes to register any of its equity securities under the
Securities Act in an initial public offering, each of the Holders, (i) if required by the managing underwriter and (ii) so long as all stockholders holding 5% or more to the total outstanding shares of Common Stock and Preferred Shares of
the Issuer on a fully-diluted basis and all officers and directors of the Issuer are also restricted in their ability to transfer securities of the Issuer by terms at least as restrictive as those contained in this Section 2.5, agrees by
acquisition of such Registrable Securities not to effect (other than pursuant to such registration) any public sale or distribution, including, but not limited to, any sale pursuant to Rule 144, of any Registrable Securities, any other equity
securities of the Issuer or any securities convertible into or exchangeable or exercisable for any equity securities of the Issuer during the time periods specified by the managing underwriter (not to exceed 180 days), to the extent timely notified
in writing by the Issuer or the managing underwriter. Each holder hereby agrees to enter into a customary agreement with the managing underwriter for the initial public offering to the effect set forth in the preceding sentence. If and whenever the
Issuer is required to use its best efforts to effect the registration of any Registrable Securities under the Securities Act pursuant to Section 2.1 or 2.2, the Issuer, if required by the managing underwriter in an underwritten offering, shall
not effect (other than pursuant to such registration or a Special Registration) any public sale or distribution of any other equity securities of the Issuer or any securities convertible into or exchangeable or exercisable for any equity securities
of the Issuer during the 10 days prior to, and for 90 days (or 180 days in the case of an initial public offering) 

  
 - 13 - 

 
after, the effective date of such registration, to the extent timely notified in writing by the managing underwriter. In addition, in such circumstances, the Issuer shall use its best efforts to
cause its directors and officers and all holders of 5% or more of its equity securities (other than the Holders) not to effect (other than pursuant to such registration) any public sale or distribution, including, but not limited to, any sale
pursuant to Rule 144, of any equity securities of the Issuer or any securities convertible into or exchangeable or exercisable for any equity securities of the Issuer during the 10 days prior to, and for 90 days (or 180 days in the case of an
initial public offering) after, the effective date of such registration, to the extent timely notified in writing by the managing underwriter. 

2.6 Preparation; Reasonable Investigation. In connection with the preparation and filing of each Registration Statement
registering Registrable Securities under the Securities Act, the Issuer shall give the Holders of such Registrable Securities so to be registered and their underwriters or placement agents, if any, and their respective counsel and accountants, the
opportunity to participate in the preparation of such Registration Statement, each Prospectus included therein or filed with the SEC, and each amendment thereof or supplement thereto, and shall, upon reasonable advance notice and during normal
business hours, give one representative of the Investors such access to all pertinent financial, corporate and other documents and properties of the Issuer and its Subsidiaries, and such opportunities to discuss the business of the Issuer with its
officers, directors, employees and the independent registered public accounting firm that has issued audit reports on its financial statements as shall be reasonably necessary, in the opinion of such Holders’ and such underwriters’ or
placement agents’ respective counsel, to conduct a reasonable investigation within the meaning of the Securities Act. 

2.7 Other Registrations. If and whenever the Issuer is required to use its best efforts to effect the registration of
any Registrable Securities under the Securities Act pursuant to Section 2.1 or 2.2, and if such registration shall not have been withdrawn or abandoned, the Issuer shall not be obligated to and shall not file any Registration Statement with
respect to any of its securities (including Registrable Securities) under the Securities Act (other than a Special Registration), whether of its own accord or at the request or demand of any holder or holders of such securities, until a period of
180 days shall have elapsed from the effective date of such previous registration, provided that the Issuer shall not be prohibited from filing a registration statement by virtue of this Section 2.7 more than once in a 360 day period.

 2.8 Indemnification. 

(a) Indemnification by the Issuer. In the event of any registration of any Registrable Securities under the Securities
Act pursuant to Section 2.1 or 2.2, the Issuer shall indemnify and hold harmless the seller of such securities, its directors, officers, and employees, each other person who participates as an underwriter, broker or dealer in the offering or
sale of such securities and each other person, if any, who controls such seller or any such participating person within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and all losses,
claims, damages or liabilities, joint or several, to which such seller or any such director, officer, employee, participating person or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions or proceedings in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement under which such securities
were registered under the Securities Act, any Prospectus or preliminary prospectus included therein, or any amendment or supplement thereto, or (ii) any omission or alleged omission to state a material fact required to be stated in any such
Registration Statement, Prospectus, preliminary prospectus, amendment or supplement or necessary to make the statements therein not misleading; and the Issuer shall reimburse such seller and each such director, officer, employee, participating
person and controlling person for any legal or any other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, liability, action or proceeding as such expenses are incurred; provided that the
Issuer shall not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon an untrue statement or omission made in any such Registration Statement, Prospectus, preliminary
prospectus, amendment or supplement in reliance upon and in conformity with written information furnished to the Issuer by such seller or participating person expressly for use in the preparation thereof. 

  
 - 14 - 

 (b) Indemnification by the Seller. In the event of any registration of any
Registrable Securities under the Securities Act pursuant to Section 2.1 or 2.2, each of the prospective sellers of such securities, severally and not jointly, will indemnify and hold harmless the Issuer, each director of the Issuer, each
officer of the Issuer who shall sign such Registration Statement, each other person who participates as an underwriter, broker or dealer in the offering or sale of such securities and each other person, if any, who controls the Issuer or such other
participating person within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any and all losses, claims, damages or liabilities, joint or several, to which the Issuer or any such director, officer,
participating person or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of or are based upon any untrue
statement or alleged untrue statement of a material fact contained in any Registration Statement under which such securities were registered under the Securities Act, any Prospectus or preliminary prospectus included therein, or any amendment or
supplement thereto, or any omission or alleged omission to state a material fact with respect to such seller required to be stated in any such Registration Statement, Prospectus, preliminary prospectus, amendment or supplement or necessary to make
the statements therein not misleading if such statement or omission was made in reliance upon and in conformity with written information furnished to the Issuer by such seller expressly for use in the preparation of any such Registration Statement,
Prospectus, preliminary prospectus, amendment or supplement; provided that the liability of each such seller shall be in proportion to and limited to the net amount received by such seller (after deducting any underwriting discount and expenses)
from the sale of Registrable Securities pursuant to such Registration Statement. 
 (c) Notices of Claims, etc.
Promptly after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to in the preceding paragraphs of this Section 2.8, such indemnified party shall, if a claim in respect thereof
is to be made against an indemnifying party hereunder, give prompt written notice to the latter of the commencement of such action, provided that the failure of any indemnified party to give notice as provided therein shall not relieve the
indemnifying party of its obligations under the preceding paragraphs of this Section 2.8 unless the failure to provide prompt written notice shall cause actual prejudice to the indemnifying party. In case any such action is brought against an
indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party shall have the right to retain counsel reasonably satisfactory to such indemnified party to defend against such proceeding and shall pay the
reasonable fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel and the payment of such fees by the indemnifying party, or (ii) the named parties to any such
proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them or
(iii) the indemnifying party has not retained counsel to defend such proceeding, in which case (under any of such clauses (i), (ii) or (iii)) it is understood that (x) the indemnifying party shall not, in connection with any
proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate firm for all such indemnified parties and (y) such firm shall be designated in writing by the Holders of a
majority of the Registrable Securities included in such Registration Statement in the case of parties indemnified pursuant to Section 2.8(a) and by the Issuer in the case of parties indemnified pursuant to Section 2.8(b). No indemnifying
party, in the defense of any such claim or litigation, shall, except with the consent of such indemnified party, which consent shall not be unreasonably withheld, consent to entry of any judgment or enter into any settlement of any pending or
threatened action in respect of which any indemnified party is or could have been a party and indemnity was sought hereunder by such indemnified party unless such judgment or settlement includes as an

  
 - 15 - 

 
unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

(d) Other Indemnification. Indemnification similar to that specified in the preceding paragraphs of this
Section 2.8 (with appropriate modifications) shall be given by the Issuer and each seller of Registrable Securities with respect to any required registration or other qualification of such Registrable Securities under any federal or state law
or regulation of governmental authority other than the Securities Act. 
 (e) Other Remedies. If for any reason the
foregoing indemnity is unavailable, or is insufficient to hold harmless an indemnified party, other than by reason of the exceptions provided therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified
party as a result of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in connection with the
statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Issuer or the Holders of Registrable Securities covered by the Registration Statement in question and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
 The
Issuer and the Holders agree that it would not be just and equitable if contribution pursuant to this Section 2.8 were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable
considerations referred to in the immediately preceding paragraph. The amount paid or payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in the immediately preceding paragraph of this
Section 2.8 shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. No party shall be liable for
contribution under this Section 2.8(e) except to the extent and under such circumstances as such party would have been liable to indemnify under this Section 2.8 if such indemnification were enforceable under applicable law. 

(f) Officers and Directors. As used in this Section 2.8, the terms “officers” and “directors”
shall include the partners of Holders that are partnerships and the members of Holders that are limited liability companies. 

2.9 Expenses. The Issuer shall pay all Registration Expenses in connection with each registration of Registrable
Securities pursuant to this Section 2. All other expenses shall be borne by the Holders participating in such registration. 

2.10 Termination. All of the Issuer’s obligations to register Registrable Securities under Sections 2.1 and 2.2
shall terminate upon the earliest of (a) five years after the closing of an initial public offering, (b) the date on which no Holder holds any Registrable Securities or (c) a Company Sale. 

3. Covenants of the Issuer. The Issuer shall comply with the covenants set forth in Sections 3.1 through 3.7: 

  
 - 16 - 

 3.1 Financial Statements. The Issuer shall maintain a system of accounts
in accordance with GAAP applied on a consistent basis, keep full and complete financial records, and, so long as the Issuer has not effected a Qualified Public Offering, the Issuer shall: 

(a) furnish to each Significant Holder, within 120 days after the end of each fiscal year, an audited balance sheet of the
Issuer as at the end of such year, together with related audited statements of operations and cash flows of the Issuer for such year, examined and reported upon by the Issuer’s independent public accountants reasonably satisfactory to the
Significant Holders, prepared in accordance with GAAP and certified by Chief Financial Officer of the Issuer; 
 (b) furnish
to each Significant Holder, within 45 days after the end of each fiscal quarter, unaudited balance sheets and statements of operations and cash flows of the Issuer, such balance sheets to be as of the end of such quarter and such statements of
operations and cash flows to be both for the year- to-date period as of the end of such quarter and for the quarter, prepared in accordance with GAAP and certified by the Chief Financial Officer of the Issuer, together with comparisons of actual
results versus the results for comparable periods in the preceding fiscal year and versus the results from the Issuer’s budget through such period; 

(c) furnish to each Significant Holder, within 30 days after the end of each month, unaudited balance sheets and statements of
operations and cash flows of the Issuer, such balance sheets to be as of the end of such month and such statements of operations and cash flows to be both for the year-to-date period as of the end of such month and for the month, prepared in
accordance with GAAP and certified by the Chief Financial Officer of the Issuer, together with comparisons of actual results versus the results for comparable periods in the preceding fiscal year and versus the results from the Issuer’s budget
through such period; 
 (d) furnish to each Significant Holder such other information as the Holders may reasonably request
in connection with any of the transactions entered into or proposed to be entered into by the Issuer that are not in the ordinary course of the Issuer’s business; and 

(e) except as may otherwise be agreed by the Board of Directors of the Issuer, including at least three Senior Preferred
Designees, furnish to the Board of Directors of the Issuer and any Observer (as defined in the Stockholders Agreement) (i) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business
plan for the next fiscal year, prepared on a monthly basis, (ii) notices of any pending or threatened litigation promptly upon becoming aware of such litigation, (iii) upon filing, copies of all filings made with the Securities and
Exchange Commission and (iv) monthly, an updated capitalization table of the Issuer, setting forth the outstanding securities of the Issuer and the holders thereof as of the date of delivery of such table to the Board of Directors. 

Notwithstanding the foregoing, the Issuer shall not be required to furnish the reports or other information contemplated by this
Section 3.1 to Novartis or any of its Affiliates if such entity is determined by the Board of Directors of the Issuer not to be a Financial Fund. 

3.2 Directors’ Indemnification and Insurance. The Certificate of Incorporation or Bylaws of the Issuer shall at all
times provide for indemnification of the directors and limitations on the liability of the directors to the fullest extent permitted under applicable state law. The Issuer will obtain and at all times maintain on reasonable business terms
directors’ and officers’ liability insurance coverage. 

  
 - 17 - 

 3.3 Inspection. The Issuer shall, upon reasonable prior notice to the
Issuer and during normal business hours, permit one authorized representative of any Investor to visit and inspect any of the properties of the Issuer, including its books of account, and to discuss its affairs, finances and accounts with its
officers and independent accountants, all at reasonable times and at such Investor’s expense; provided, that no action requested under this Section 3.3 shall unreasonably interfere with the normal business operations of the Issuer;
provided, further, that the Issuer shall not be required to permit any action requested under this Section 3.3 by Novartis or any of its Affiliates if such entity is determined by the Board of Directors of the Issuer not to be a
Financial Fund. 
 3.4 Stock Incentive Plans. The Issuer shall not, without the approval of the Board of Directors,
including at least three Senior Preferred Designees, (i) create any stock option plan or similar stock option, equity participation or bonus arrangement or (ii) allocate, grant or otherwise award any capital stock or any securities
convertible into, exercisable for or evidencing the right to purchase shares of capital stock to employees, directors or consultants of the Issuer. Unless otherwise approved by the Board of Directors, including at least three Senior Preferred
Designees, all employees and consultants of the Issuer who purchase, receive options to purchase, or receive awards of shares of the Issuer’s capital stock after the date hereof shall be required to execute restricted stock or option
agreements, as applicable, providing for vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining
shares vesting in equal monthly installments over the following thirty-six (36) months. 
 3.5 Confidentiality.
Each Investor agrees that such Investor will keep confidential and will not disclose, divulge or use for any purpose, other than to monitor its investment in the Issuer, any Confidential Information, unless such Confidential Information (a) is
known or becomes known to the public in general (other than as a result of a breach of this Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investors without use of the Issuer’s
Confidential Information or (c) is or has been made known or disclosed to the Issuer by a third party without a breach of any obligation of confidentiality such third party may have to the Issuer; provided, however, that a Investor may disclose
Confidential Information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Issuer, (ii) to any prospective purchaser
of any Shares from such Investor as long as such prospective purchaser agrees to be bound by the provisions of this Section 3.5, (iii) to any Affiliate of such Investor, provided that such party is obligated not to disclose, divulge or use
any Confidential Information to the same extent as the Investors, or (iv) as may otherwise be required by law, provided that the Investor takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding the
foregoing, such information shall not be deemed confidential for the purpose of enforcing this Agreement. 
 3.6 Employees
and Consultants. The Issuer hereby covenants and agrees that (a) each employee and officer hired by the Issuer shall sign a Nondisclosure and Developments Agreement substantially in the form attached to the Purchase Agreement as
“Exhibit G” prior to the commencement of such person’s employment with the Issuer and (b) each consultant engaged by the Issuer shall agree in writing to be bound by nondisclosure and assignment of inventions terms consistent
with nondisclosure and assignment of inventions terms previously approved by the Board of Directors. 
 3.7 Registration
Rights. The Issuer hereby covenants and agrees that it shall not hereafter grant to any Person any right to register or qualify stock of the Issuer under federal or state securities laws, unless it shall have first obtained the written consent
of the Holder or Holders of the Senior Required Securities. 

  
 - 18 - 

 3.8 Compensation Arrangements. The Issuer hereby covenants and agrees that
it shall not enter into any compensation arrangement, including the issuance of restricted stock or stock options, with any officer or director of the Issuer who is affiliated with a Series E Investor without the approval of the Board of Directors,
including at least three Senior Preferred Designees. 
 3.9 Termination. All of the Issuer’s obligations under
Sections 3.1 through 3.8 shall terminate upon the earliest of (a) the closing of an initial public offering pursuant to an effective registration agreement under the Securities Act and (b) the date on which no Holder holds any Registrable
Securities or (c) a Company Sale. 
 4. Miscellaneous. 

4.1 Rule 144; Legended Securities; etc. 

(a) After the earliest of (i) the closing of the sale of securities of the Issuer pursuant to a Registration Statement,
(ii) the registration by the Issuer of a class of securities under Section 12 of the Exchange Act, or (iii) the issuance by the Issuer of an offering circular pursuant to Regulation A under the Securities Act, the Issuer agrees to:

 (i) make and keep current public information about the Issuer available, as those terms are understood and defined in
Rule 144; 
 (ii) use its best efforts to file with the SEC in a timely manner all reports and other documents required of
the Issuer under the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 

(iii) furnish to any holder of Registrable Securities upon request (i) a written statement by the Issuer as to its
compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), (ii) a copy of the most recent annual or quarterly report of the
Issuer, and (iii) such other reports and documents of the Issuer as such holder may reasonably request to avail itself of any similar rule or regulation of the SEC allowing it to sell any such securities without registration. 

(b) The Issuer shall issue new certificates for Registrable Securities without a legend restricting further transfer if
(i) such securities have been sold to the public pursuant to an effective Registration Statement under the Securities Act (other than Form S-8 if the Holder of such Registrable Securities is an Affiliate) or Rule 144, or (ii) (x) such
issuance is otherwise permitted under the Securities Act, (y) the Holder of such shares has delivered to the Issuer an opinion of counsel, which opinion and counsel shall be reasonably satisfactory to the Issuer, to such effect and (z) the
Holder of such shares expressly requests the issuance of such certificates in writing. 
 4.2 Entire Agreement; Amendments
and Waivers. This Agreement constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior agreements and understanding among them, including the Fourth Amended and Restated Investor Rights
Agreement as to such subject matter. This Agreement may be amended, modified, changed, discharged, waived or terminated, and the Issuer may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if
the Issuer shall have obtained the written consent to such amendment, modification, change, discharge, waiver, termination, action or omission to act, of (a) the Holders of at least a majority of the Registrable Securities, (b) the Holders
of the Senior Required 

  
 - 19 - 

 
Securities and (c) the holders of at least seventy-five percent (75%) of the combined voting power of the issued and outstanding Senior Preferred Stock (voting as a single class in
accordance with Article FOURTH, Part C, Subsection 3.1 of the Certificate of Incorporation); provided that no consent shall be required under clauses (a), (b) or (c) for any amendments to this Agreement that are effected as a condition to
or as part of a Qualified Liquidation Event (as defined in the Certificate of Incorporation); provided further that the Company may amend this Agreement without the consent of the Investors solely to add investors that purchase Series E Preferred
Stock pursuant to Section 2.4 of the Purchase Agreement to Schedule I (which investors shall be included in the definition of “Investors” hereunder upon executing and delivering to the Company a signature page to the Purchase
Agreement). Notwithstanding the foregoing, (i) a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders whose securities are being sold pursuant to a Registration
Statement and that does not directly or indirectly affect, impair, limit or compromise the rights of other Holders may be given by Holders of at least a majority of the Registrable Securities being sold by such Holders pursuant to such Registration
Statement and (ii) this Agreement may not be amended, modified, changed, waived, discharged or terminated and the observance of any term hereunder may not be waived with respect to any Holder without the written consent of such Holder if such
amendment, modification, waiver, discharge or termination uniquely applies to such Holder; provided, however, that the provisions of this sentence may not be amended, modified or supplemented except in accordance with the provisions of
the immediately preceding sentence. No amendment, modification or discharge of this Agreement, and no waiver hereunder, shall be valid or binding unless set forth in writing. Any such waiver shall constitute a waiver only with respect to the
specific matter described in such writing and shall in no way impair the rights of the party or parties granting such waiver in any other respect or at any other time. 

4.3 Successors, Assigns and Transferees. 

(a) This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective permitted
successors, assigns and transferees. Any Holder may assign its rights applicable to the shares transferred hereunder to: 

(i) successors, assigns and transferees of such Holder by merger or consolidation or otherwise by operation of law, 

(ii) any transferee who acquires at least 20% of the Registrable Securities owned by a transferring Holder; or 

(iii) any partner, member or stockholder or other Affiliate of a Holder. 

(b) In addition, such assignment is conditioned upon: (i) such Investor or other Holder agreeing in writing with the
transferee or assignee to assign such rights, and the Issuer receiving written notice from the assigning party at the time of such assignment stating the name and address of the assignee and identifying the capital stock of the Issuer as to which
the rights in question are being assigned; and (ii) the transferee or assignee agreeing in writing to be bound by all of the terms and conditions of this Agreement. 

4.4 Notices. Any notice required to be given hereunder shall be sufficient if in writing, and sent by facsimile
transmission, by courier service (with proof of service), hand delivery or certified or registered mail (return receipt requested and first-class postage prepaid), addressed as set forth below: 

(1) if to the Issuer, to it at: 

  
 - 20 - 

 Tokai Pharmaceuticals, Inc. 

1 Broadway, 14th floor 

Cambridge, MA 02142 

Facsimile: (617) 977-8607 

Attention: Chief Executive Officer 

with a copy to: 

WilmerHale 

60 State Street 

Boston, MA 02109 

Facsimile: (617) 526-5000 

Attention: Stuart M. Falber, Esq. 

(2) if to any other Holder, to it at the address set forth next to its name on Schedule I. 

or, in any case, at such other address or facsimile number as shall have been furnished in writing by such party to all of the other parties hereto. Any party
may give any notice or other communication in connection herewith using any other means (including, but not limited to, messenger service, telex or ordinary mail), but no such notice or other communication shall be deemed to have been duly given
unless and until it is actually received by the individual for whom it is intended. 
 4.5 No Inconsistent Agreements.
The Issuer shall not hereafter enter into any agreement, or amend any existing agreement, with respect to its securities if such agreement would be inconsistent with the rights granted to the Holders by this Agreement. 

4.6 Enforcement of Agreement, 

(a) The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were
not performed in accordance with its specific terms or was otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms
and provisions hereof, this being in addition to any other remedy to which they are entitled at law or in equity. 
 (b) The
prevailing party in any judicial action shall be entitled to receive from the other party reimbursement for the prevailing party’s reasonable attorneys’ fees and disbursements, and court costs. 

4.7 Severability. Any term or provision of this Agreement that is invalid or unenforceable in any jurisdiction shall, as
to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this Agreement or affecting the validity or enforceability of any of the terms
or provisions of this Agreement in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as is enforceable. 

4.8 Headings. Headings of this Agreement are for the convenience of the parties only, and shall be given no substantive
or interpretive effect whatsoever. 
 4.9 Counterparts. This Agreement may be executed by the parties hereto in
separate counterparts (and may be delivered by facsimile), each of which when so executed and delivered shall be an original, but all such counterparts shall together constitute one and the same instrument. Each

  
 - 21 - 

 
counterpart may consist of a number of copies hereof each signed by less than all, but together signed by all, of the parties hereto. 

4.10 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State
of Delaware without regard to its rules of conflict of laws. 
 4.11 No Third Party Beneficiaries. Except as provided
in Section 2.8, nothing in this Agreement shall confer any rights upon any person or entity other than the parties hereto, each such party’s respective successors and permitted assigns. 

4.12 Effectiveness. This Agreement shall become effective when executed by (a) the Issuer; (b) the Holders of
a majority of the Registrable Securities and the Holders of the Senior Required Securities, as such terms are defined in the Fourth Amended and Restated Investor Rights Agreement; and (c) the holders of at least seventy-five percent
(75%) of the combined voting power of the issued and outstanding Senior Preferred Stock (voting as a single class in accordance with Article FOURTH, Part C, Subsection 3.1 of the Certificate of Incorporation, upon which time the Fourth Amended
and Restated Investor Rights Agreement shall be amended and restated in its entirety to read as set forth herein and this Agreement shall be binding upon each of the parties to the Fourth Amended and Restated Investor Rights Agreement (and any
successor, assignee or transferee of any such party), notwithstanding any failure by any such party to sign a counterpart signature page hereto. 

4.13 Limitations on Liability. The limitations on liability of Queensland Biocapital Funds No. 1 and Queensland
Biocapital Funds No. 2, as set forth in Exhibit A attached hereto, are incorporated by reference herein as if set forth in its entirety herein. 

[Remainder of Page Intentionally Left Blank] 

  
 - 22 - 

 IN WITNESS WHEREOF, each of the undersigned has executed this Agreement or caused this Agreement
to be executed on its behalf as of the date first written above. 
  

			
	TOKAI PHARMACEUTICALS, INC.
		
	By:	 	/s/ Jodie P. Morrison
		 	 Jodie P. Morrison
 Chief Executive
Officer

	
	INVESTORS:
	
	Counterpart signature pages attached.

  
 - 23 - 

 SCHEDULE I 

INVESTORS 
 Name of Investors 

 

	
	 APPLE TREE PARTNERS II, L.P.
 APPLE TREE
PARTNERS II, L.P.- ANNEX
 47 Hulfish Street, Suite 441

Princeton, NJ 08542
 Attention: Seth Harrison

	
	 Novartis BioVentures Ltd.
 Attn: Henri Simon
Zivi
 131 Front Street
 Hamilton HM 12

Bermuda

	
	But for mail, to:
	
	 Novartis BioVentures Ltd.
 PO Box HM 2899

Hamilton HM LX Bermuda
  

With a copy to:
  

Novartis Venture Fund
 Attn: Campbell Murray

Five Cambridge Center, Suite 603
 Cambridge, MA 02142

 
 and

	
	 Edwards Wildman Palmer LLP
 Attn: Al Sokol

111 Huntington Avenue
 Boston, MA 02199 USA

	
	 Muneer A. Satter Revocable Trust
 The Satter
Foundation
 Satter Children’s Trust I
 Satter Family
Trust
 Kristen Hayler Hertel Revocable Trust
 c/o Muneer A.
Satter
 Satter Investment Management, LLC
 676 North Michigan
Ave., Suite 4000
 Chicago, IL 60611

  
 - 24 - 

	
	 QBF No. 1 Pty Ltd
 QBF No. 2 Pty Ltd

ACN 100 826 686
 L6 Central Plaza II, 66 Eagle Street

GPO Box 2242 Brisbane
 QLD 4001 Australia

	
	 Jon B. Platt
 393 Arbor Street

Lunenburg, MA 01462

	
	 Nickeli Holdings Pty. Ltd.
 30 Wolseley Road

Mosman N.S.W. 2088
 Australia

	
	 Warman Investments Pty. Ltd.
 Level 1, 4-10
Bridge Street
 Pymble 2073
 Australia

	
	 R.B. Thomas Family Trust
 R.B. Thomas
Superannuation Fund
 56 Coolong Road
 Vaucluse N.S.W. 2030

Australia

	
	 Timothy J. Barberich
 40 Elm Steet

Concord, MA 01742

	
	 Vial Superannuation Fund
 67 Denbigh Road

Armadale, Melbourne
 Victoria

Australia 3143

	
	 Neil Chatfield
 4 Hillcrest Avenue

Kew, Victoria
 Australia 3101

	
	 WS Investment Company, LLC (2013A)
 650 Page
Mill Road
 Palo Alto, CA 94304

  
 - 25 - 

	
	 Namarong Investments Pty Ltd as Trustee
 for the
Hansen Investment Trust
 40 Claremont Street
 South Yarra
VIC
 Australia 3141

  
 - 26 - 

 EXHIBIT A 

LIMITATIONS OF LIABILITY OF QBF 
  

	1	Limited capacity 

 QBF No. 1 Pty Ltd (“QBFl”) enters into this
agreement only in its capacity as trustee of the Queensland BioCapital Fund No 1 and in no other capacity. A liability arising under or in connection with this agreement is limited to and can be enforced against QBF1 only to the extent to which it
can be satisfied out of the property of the Queensland BioCapital Fund No 1. This limitation of QBF1’s liability applies despite any other provisions of this agreement and extends to all liabilities and obligations of QBF1 in any way connected
with any representation, warranty, conduct, omission, agreement or transaction related to this agreement. 
  

	2	Limited rights to sue 

 The parties may not sue QBF1 in any capacity other than as
trustee of the Queensland BioCapital Fund No 1, including seeking the appointment of a receiver (except in relation to the property of Queensland BioCapital Fund No 1), a liquidator, an administrator or any similar persons to QBF1 or approve any
liquidation, administration or arrangement of affecting QBF1 (except in relation to the property of Queensland BioCapital Fund No 1). 
  

	3	Exceptions 

 The provisions of clauses 1 and 2 shall not apply to any obligation
or liability of QBF1 to the extent that it is not satisfied because under the constitution establishing the Queensland BioCapital Fund No 1 or by operation of law there is a reduction in the extent of QBF1’s indemnification from the assets of
the Queensland BioCapital Fund No 1 as a result of QBF1’s fraud, negligence or breach of trust. 
  

	4	Limitation on authority 

 No attorney, agent, receiver and manager appointed in
accordance with this agreement has authority to act on behalf of QBF1 in a way which exposes QBF1 to any personal liability in contravention of clauses 1 and 2, and no act or omission of any such person will be considered fraud, negligence or breach
of trust of QBF1 for the purpose of clause 3. 
  

	5	Limited capacity 

 QBF No. 2 Pty Ltd (“QBF2”) enters into this
agreement only in its capacity as trustee of the Queensland BioCapital Fund No 2 and in no other capacity. A liability arising under or in connection with this agreement is limited to and can be enforced against QBF2 only to the extent to which it
can be satisfied out of the property of the Queensland BioCapital Fund No 2. This limitation of QBF2’s liability applies despite any other provisions of this agreement and extends to all liabilities and obligations of QBF2 in any way connected
with any representation, warranty, conduct, omission, agreement or transaction related to this agreement. 
  

	6	Limited rights to sue 

 The parties may not sue QBF2 in any capacity other than as
trustee of the Queensland BioCapital Fund No 2, including seeking the appointment of a receiver (except in relation to the property of Queensland BioCapital Fund No 2), a liquidator, an administrator or any similar persons to QBF2 or approve any
liquidation, administration or arrangement of affecting QBF2 (except in relation to the property of Queensland BioCapital Fund No 2). 

  
 - 27 - 

	7	Exceptions 

 The provisions of clauses 5 and 6 shall not apply to any obligation
or liability of QBF2 to the extent that it is not satisfied because under the constitution establishing the Queensland BioCapital Fund No 1 or by operation of law there is a reduction in the extent of QBF2’s indemnification from the assets of
the Queensland BioCapital Fund No 2 as a result of QBF2’s fraud, negligence or breach of trust. 
  

	8	Limitation on authority 

 No attorney, agent, receiver and manager appointed in
accordance with this agreement has authority to act on behalf of QBF2 in a way which exposes QBF2 to any personal liability in contravention of clauses 5 and 6, and no act or omission of any such person will be considered fraud, negligence or breach
of trust of QBF2 for the purpose of clause 7. 

  
 - 28 -EX-10.2

 Exhibit 10.2 

TOKAI PHARMACEUTICALS, INC. 

2007 STOCK INCENTIVE PLAN 
 1.
Purpose 
 The purpose of this 2007 Stock Incentive Plan (the “Plan”) of Tokai Pharmaceuticals, Inc. a Delaware corporation
(the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by
providing such persons with equity ownership opportunities and performance-based incentives that are intended to align their interests with those of the Company’s stockholders. Except where the context otherwise requires, the term
“Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations promulgated
thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the
“Board”). 
 2. Eligibility 

All of the Company’s employees, officers, directors, consultants and advisors are eligible to receive options, restricted stock,
restricted stock units and other stock-based awards (each, an “Award”) under the Plan. Each person who receives an Award under the Plan is deemed a “Participant”. 

3. Administration and Delegation 
 (a)
Administration by Board of Directors. The Plan will be administered by the Board. The Board shall have authority to grant Awards and to adopt, amend and repeal such administrative rules, guidelines and practices relating to the Plan as it
shall deem advisable. The Board may correct any defect, supply any omission or reconcile any inconsistency in the Plan or any Award in the manner and to the extent it shall deem expedient to carry the Plan into effect and it shall be the sole and
final judge of such expediency. All decisions by the Board shall be made in the Board’s sole discretion and shall be final and binding on all persons having or claiming any interest in the Plan or in any Award. No director or person acting
pursuant to the authority delegated by the Board shall be liable for any action or determination relating to or under the Plan made in good faith. 

(b) Appointment of Committees. To the extent permitted by applicable law, the Board may delegate any or all of its powers under the
Plan to one or more committees or subcommittees of the Board (a “Committee”). All references in the Plan to the “Board” shall mean the Board or a Committee of the Board or the officers referred to in Section 3(c) to the
extent that the Board’s powers or authority under the Plan have been delegated to such Committee or officers. 
 (c) Delegation to
Officers. To the extent permitted by applicable law, the Board may delegate to one or more officers of the Company the power to grant Awards to employees or officers of the Company or any of its present or future subsidiary corporations and to
exercise such other powers under the Plan as the Board may determine, provided that the Board shall fix the terms of the Awards to be granted by such officers (including the exercise price of such Awards, which may include a formula by which the
exercise price will be determined) and the maximum number of shares subject to Awards that the officers may grant; provided further, however, that no officer shall be authorized to grant Awards to any “executive officer” of the Company (as
defined by Rule 3b-7 under the Securities Exchange Act of 

  

 
1934, as amended (the “Exchange Act”)) or to any “officer” of the Company (as defined by Rule 16a-1 under the Exchange Act).] 

4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to 235,519 shares of common stock,
$0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as the result of shares of
Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered by such Award shall again
be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the grant of Awards under the
Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued
shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total number of shares of Common
Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable percentage as calculated in accordance with the conditions and exclusions
of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time the calculation is made. 

5. Stock Options 
 (a) General.
The Board may grant options to purchase Common Stock (each, an “Option”) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and limitations applicable to
the exercise of each Option, including conditions relating to applicable federal or state securities laws, as it considers necessary or advisable. An Option which is not intended to be an Incentive Stock Option (as hereinafter defined) shall be
designated a “Nonstatutory Stock Option”. 
 (b) Incentive Stock Options. An Option that the Board intends to be an
“incentive stock option” as defined in Section 422 of the Code (an “Incentive Stock Option”) shall only be granted to employees of Tokai Pharmaceuticals, Inc., any of Tokai Pharmaceuticals, Inc.‘s present or future
parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Code, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code, and shall be subject to and shall be construed
consistently with the requirements of Section 422 of the Code. The Company shall have no liability to a Participant, or any other party, if an Option (or any part thereof) that is intended to be an Incentive Stock Option is not an Incentive
Stock Option or for any action taken by the Board pursuant to Section 9(f), including without limitation the conversion of an Incentive Stock Option to a Nonstatutory Stock Option. 

(c) Exercise Price. The Board shall establish the exercise price of each Option and specify such exercise price in the applicable
option agreement. 
 (d) Duration of Options. Each Option shall be exercisable at such times and subject to such terms and conditions
as the Board may specify in the applicable option agreement. 
 (e) Exercise of Option. Options may be exercised by delivery to the
Company of a written notice of exercise signed by the proper person or by any other form of notice (including electronic notice) approved by the Board together with payment in full as specified in Section 5(f) for the number of shares

  
 - 2 - 

 
for which the Option is exercised. Shares of Common Stock subject to the Option will be delivered by the Company following exercise either as soon as practicable or, subject to such conditions as
the Board shall specify, on a deferred basis (with the Company’s obligation to be evidenced by an instrument providing for future delivery of the deferred shares at the time or times specified by the Board). 

(f) Payment Upon Exercise. Common Stock purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:

 (1) in cash or by check, payable to the order of the Company; 

(2) except as the Board may otherwise provide in an option agreement, by (i) delivery of an irrevocable and unconditional undertaking by
a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Participant to the Company of a copy of irrevocable and unconditional instructions to a
creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding; 

(3) when the Common Stock is registered under the Exchange Act, by delivery of shares of Common Stock owned by the Participant valued at their
fair market value as determined by (or in a manner approved by) the Board (“Fair Market Value”), provided (i) such method of payment is then permitted under applicable law, (ii) such Common Stock, if acquired directly from the
Company, was owned by the Participant for such minimum period of time, if any, as may be established by the Board in its discretion and (iii) such Common Stock is not subject to any repurchase, forfeiture, unfulfilled vesting or other similar
requirements; 
 (4) to the extent permitted by applicable law and by the Board, by (i) delivery of a promissory note of the
Participant to the Company on terms determined by the Board, or (ii) payment of such other lawful consideration as the Board may determine; or 

(5) by any combination of the above permitted forms of payment. 

(g) Substitute Options. In connection with a merger or consolidation of an entity with the Company or the acquisition by the Company of
property or stock of an entity, the Board may grant Options in substitution for any options or other stock or stock-based awards granted by such entity or an affiliate thereof. Substitute Options may be granted on such terms as the Board deems
appropriate in the circumstances, notwithstanding any limitations on Options contained in the other sections of this Section 5 or in Section 2. Substitute Options shall not count against the overall share limit set forth in
Section 4(a), except as may be required by reason of Section 422 and related provisions of the Code. 
 (h) Repricing of
Options. The Board may, without stockholder approval, amend any outstanding Option granted under the Plan to provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option. The Board
may also, without stockholder approval, cancel any outstanding option (whether or not granted under the Plan) and grant in substitution therefor new Awards under the Plan covering the same or a different number of shares of Common Stock and having
an exercise price per share lower than the then-current exercise price per share of the cancelled option. 
 6. Restricted Stock; Restricted Stock
Units 
 (a) General. The Board may grant Awards entitling recipients to acquire shares of Common Stock (“Restricted
Stock”), subject to the right of the Company to repurchase all or part of such shares at 

  
 - 3 - 

 
their issue price or other stated or formula price (or to require forfeiture of such shares if issued at no cost) from the recipient in the event that conditions specified by the Board in the
applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award. Instead of granting Awards for Restricted Stock, the Board may grant Awards entitling the recipient to
receive shares of Common Stock to be delivered at the time such shares of Common Stock vest (“Restricted Stock Units”) (Restricted Stock and Restricted Stock Units are each referred to herein as a “Restricted Stock Award”). 

(b) Terms and Conditions. The Board shall determine the terms and conditions of a Restricted Stock Award, including the conditions for
repurchase (or forfeiture) and the issue price, if any. 
 (c) Stock Certificates. Any stock certificates issued in respect of a
Restricted Stock Award shall be registered in the name of the Participant and, unless otherwise determined by the Board, deposited by the Participant, together with a stock power endorsed in blank, with the Company (or its designee). At the
expiration of the applicable restriction periods, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to the Participant or if the Participant has died, to the beneficiary designated, in a manner
determined by the Board, by a Participant to receive amounts due or exercise rights of the Participant in the event of the Participant’s death (the “Designated Beneficiary”). In the absence of an effective designation by a
Participant, “Designated Beneficiary” shall mean the Participant’s estate. 
 7. Other Stock-Based Awards 

Other Awards of shares of Common Stock, and other Awards that are valued in whole or in part by reference to, or are otherwise based on,
shares of Common Stock or other property, may be granted hereunder to Participants (“Other Stock Unit Awards”), including without limitation stock appreciation rights and Awards entitling recipients to receive shares of Common Stock to be
delivered in the future. Such Other Stock Unit Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other
Stock Unit Awards may be paid in shares of Common Stock or cash, as the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the conditions of each Other Stock Unit Award, including any purchase price applicable
thereto. 
 8. Adjustments for Changes in Common Stock and Certain Other Events 

(a) Changes in Capitalization. In the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of
shares, reclassification of shares, spin-off or other similar change in capitalization or event, or any distribution to holders of Common Stock other than an ordinary cash dividend, (i) the number and class of securities available under this
Plan, (ii) the number and class of securities and exercise price per share of each outstanding Option, (iii) the repurchase price per share subject to each outstanding Restricted Stock Award, and (iv) the terms of each other
outstanding Award shall be appropriately adjusted by the Company (or substituted Awards may be made, if applicable) to the extent determined by the Board. 

(b) Reorganization Events 

(1) Definition. A “Reorganization Event” shall mean: (a) any merger or consolidation of the Company with
or into another entity as a result of which all of the Common Stock of the Company is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (b) any exchange of all of the Common Stock of the
Company for cash, securities or other property pursuant to a share exchange transaction or (c) any liquidation or dissolution of the Company. 

  
 - 4 - 

 (2) Consequences of a Reorganization Event on Awards Other than Restricted
Stock Awards. In connection with a Reorganization Event, the Board shall take any one or more of the following actions as to all or any outstanding Awards on such terms as the Board determines: (i) provide that Awards shall be assumed, or
substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (ii) upon written notice to a Participant, provide that the Participant’s unexercised Options or other unexercised
Awards shall become exercisable in full and will terminate immediately prior to the consummation of such Reorganization Event unless exercised by the Participant within a specified period following the date of such notice, (iii) provide that
outstanding Awards shall become realizable or deliverable, or restrictions applicable to an Award shall lapse, in whole or in part prior to or upon such Reorganization Event, (iv) in the event of a Reorganization Event under the terms of which
holders of Common Stock will receive upon consummation thereof a cash payment for each share surrendered in the Reorganization Event (the “Acquisition Price”), make or provide for a cash payment to a Participant equal to (A) the
Acquisition Price times the number of shares of Common Stock subject to the Participant’s Options or other Awards (to the extent the exercise price does not exceed the Acquisition Price) minus (B) the aggregate exercise price of all such
outstanding Options or other Awards, in exchange for the termination of such Options or other Awards, (v) provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation
proceeds (if applicable, net of the exercise price thereof) and (vi) any combination of the foregoing. 
 For purposes
of clause (i) above, an Option shall be considered assumed if, following consummation of the Reorganization Event, the Option confers the right to purchase, for each share of Common Stock subject to the Option immediately prior to the
consummation of the Reorganization Event, the consideration (whether cash, securities or other property) received as a result of the Reorganization Event by holders of Common Stock for each share of Common Stock held immediately prior to the
consummation of the Reorganization Event (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock); provided, however, that if the consideration
received as a result of the Reorganization Event is not solely common stock of the acquiring or succeeding corporation (or an affiliate thereof), the Company may, with the consent of the acquiring or succeeding corporation, provide for the
consideration to be received upon the exercise of Options to consist solely of common stock of the acquiring or succeeding corporation (or an affiliate thereof) equivalent value (as determined by the Board) to the per share consideration received by
holders of outstanding shares of Common Stock as a result of the Reorganization Event. 
 To the extent all or any portion of
an Option becomes exercisable solely as a result of clause (ii) above, the Board may provide that upon exercise of such Option the Participant shall receive shares subject to a right of repurchase by the Company or its successor at the Option
exercise price; such repurchase right (x) shall lapse at the same rate as the Option would have become exercisable under its terms and (y) shall not apply to any shares subject to the Option that were exercisable under its terms without
regard to clause (ii) above. 
 (3) Consequences of a Reorganization Event on Restricted Stock Awards. Upon the
occurrence of a Reorganization Event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company under each outstanding Restricted Stock Award shall inure to the benefit of the Company’s successor and
shall apply to the cash, securities or other property which the Common Stock was converted into or exchanged for pursuant to such Reorganization Event in the same manner and to the same extent as they applied to the Common Stock subject to such
Restricted Stock Award. Upon the occurrence of a Reorganization Event involving the liquidation or dissolution of the Company, except to the extent specifically provided to the contrary in the instrument evidencing any Restricted Stock Award or any
other agreement between a Participant and the Company, all restrictions 

  
 - 5 - 

 
and conditions on all Restricted Stock Awards then outstanding shall automatically be deemed terminated or satisfied. 

9. General Provisions Applicable to Awards 

(a) Transferability of Awards. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned,
transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution or, other than in the case of an Incentive Stock Option, pursuant
to a qualified domestic relations order, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the extent relevant in the context, shall include references to authorized transferees.

 (b) Documentation. Each Award shall be evidenced in such form (written, electronic or otherwise) as the Board shall determine.
Each Award may contain terms and conditions in addition to those set forth in the Plan. 
 (c) Board Discretion. Except as otherwise
provided by the Plan, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award need not be identical, and the Board need not treat Participants uniformly. 

(d) Termination of Status. The Board shall determine the effect on an Award of the disability, death, retirement, authorized leave of
absence or other change in the employment or other status of a Participant and the extent to which, and the period during which, the Participant, or the Participant’s legal representative, conservator, guardian or Designated Beneficiary, may
exercise rights under the Award. 
 (e) Withholding. Each Participant shall pay to the Company, or make provision satisfactory to the
Company for payment of, any taxes required by law to be withheld in connection with an Award to such Participant. Except as the Board may otherwise provide in an Award, for so long as the Common Stock is registered under the Exchange Act,
Participants may satisfy such tax obligations in whole or in part by delivery of shares of Common Stock, including shares retained from the Award creating the tax obligation, valued at their Fair Market Value; provided, however, except as otherwise
provided by the Board, that the total tax withholding where stock is being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for federal and
state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares surrendered to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar
requirements. The Company may, to the extent permitted by law, deduct any such tax obligations from any payment of any kind otherwise due to a Participant. 

(f) Amendment of Award. The Board may amend, modify or terminate any outstanding Award, including but not limited to, substituting
therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option, provided that the Participant’s consent to such action shall be
required unless the Board determines that the action, taking into account any related action, would not materially and adversely affect the Participant. 

(g) Conditions on Delivery of Stock. The Company will not be obligated to deliver any shares of Common Stock pursuant to the Plan or to
remove restrictions from shares previously delivered under the Plan until (i) all conditions of the Award have been met or removed to the satisfaction of the 

  
 - 6 - 

 
Company, (ii) in the opinion of the Company’s counsel, all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable
securities laws and any applicable stock exchange or stock market rules and regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy
the requirements of any applicable laws, rules or regulations. 
 (h) Acceleration. The Board may at any time provide that any Award
shall become immediately exercisable in full or in part, free of some or all restrictions or conditions, or otherwise realizable in full or in part, as the case may be. 

10. Miscellaneous 
 (a) No Right To
Employment or Other Status. No person shall have any claim or right to be granted an Award, and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company.
The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with a Participant free from any liability or claim under the Plan, except as expressly provided in the applicable Award. 

(b) No Rights As Stockholder. Subject to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have
any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder of such shares. Notwithstanding the foregoing, in the event the Company effects a split of the Common
Stock by means of a stock dividend and the exercise price of and the number of shares subject to such Option are adjusted as of the date of the distribution of the dividend (rather than as of the record date for such dividend), then an optionee who
exercises an Option between the record date and the distribution date for such stock dividend shall be entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such Option exercise,
notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such stock dividend. 

(c) Effective Date and Term of Plan. The Plan shall become effective on the date on which it is adopted by the Board. No Awards shall
be granted under the Plan after the completion of 10 years from the earlier of (i) the date on which the Plan was adopted by the Board or (ii) the date the Plan was approved by the Company’s stockholders, but Awards previously granted
may extend beyond that date. 
 (d) Amendment of Plan. The Board may amend, suspend or terminate the Plan or any portion thereof at
any time. 
 (e) Authorization of Sub-Plans. The Board may from time to time establish one or more sub-plans under the Plan for
purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to this Plan containing (i) such limitations on the Board’s discretion under the
Plan as the Board deems necessary or desirable or (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part
of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company shall not be required to provide copies of any supplement to Participants in any jurisdiction which is not the subject of such
supplement. 
 (f) Compliance with Code Section 409A. No Award shall provide for deferral of compensation that does not comply
with Section 409A of the Code, unless the Board, at the time of grant, specifically provides that the Award is not intended to comply with Section 409A of the Code. 

  
 - 7 - 

 (g) Governing Law. The provisions of the Plan and all Awards made hereunder shall be
governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than such state. 

  
 - 8 - 

 AMENDMENT NO. 1 TO 

2007 STOCK INCENTIVE PLAN 

OF 
 TOKAI
PHARMACEUTICALS, INC. 
 The 2007 Stock Incentive Plan (the “2007 Plan”) of Tokai Pharmaceuticals, Inc. is hereby
amended as follows: 
 Section 4 of the 2007 Plan is deleted in its entirety and the following is substituted in its place:

 “4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to
441,346 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part
(including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common
Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock
available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in
whole or in part of authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option,
shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable percentage as calculated in
accordance with the conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time the calculation is
made.” 
 Adopted by the Board of Directors on June 26, 2008 

Adopted by the Stockholders on June 30, 2008           

  

 AMENDMENT NO. 2 

TO 2007 STOCK INCENTIVE PLAN 

OF 
 TOKAI
PHARMACEUTICALS, INC. 
 The 2007 Stock Incentive Plan (the “2007 Plan”) of Tokai Pharmaceuticals, Inc. is hereby amended as
follows: 
 Section 4 of the 2007 Plan is deleted in its entirety and the following is substituted in its place: 

“4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to 1,855,096
shares of common stock, $0,001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as
the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the
grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total
number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable percentage as calculated in accordance with the
conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time the calculation is made.” 

Adopted by the Board of Directors on March 3, 2009 

Adopted by the Stockholders on March 25, 2009         

  

 AMENDMENT NO. 3 TO 

2007 STOCK INCENTIVE PLAN 

OF 
 TOKAI
PHARMACEUTICALS, INC. 
 The 2007 Stock Incentive Plan (the “2007 Plan”) of Tokai Pharmaceuticals, Inc. is hereby amended as
follows: 
 Section 4 of the 2007 Plan is deleted in its entirety and the following is substituted in its place: 

“4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to 8,911,043
shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as
the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the
grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total
number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable percentage as calculated in accordance with the
conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time the calculation is made.” 

Adopted by the Board of Directors on May 5, 2009 

Adopted by the Stockholders on May 5, 2009           

  

 AMENDMENT NO. 4 TO 

2007 STOCK INCENTIVE PLAN OF TOKAI PHARMACEUTICALS, INC. 

The 2007 Stock Incentive Plan (the “2007 Plan”) of Tokai Pharmaceuticals, Inc. is hereby amended as follows: 

Section 4 of the 2007 Plan is deleted in its entirety and the following is substituted in its place: 

“4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to 12,709,571
shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as
the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock tendered to the Company by a Participant to exercise an Award shall be added to the number of shares of Common Stock available for the
grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of
authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of grant of such Option, shall the total
number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable percentage as calculated in accordance with the
conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time the calculation is made.” 

Adopted by the Board of Directors on September 7, 2011 

Adopted by the Stockholders on September 9, 2011           

  

 AMENDMENT NO. 5 TO 

2007 STOCK INCENTIVE PLAN 

OF 
 TOKAI
PHARMACEUTICALS, INC. 
 The Amended and Restated 2007 Stock Incentive Plan dated April 9, 2010 (the “2007 Plan”) of
Tokai Pharmaceuticals, Inc. is hereby amended as follows: 
 Section 4 of the 2007 Plan is deleted in its entirety and the following is
substituted in its place: 
 “4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under
the Plan for up to 16,653,382 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in
whole or in part (including as the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued,
the unused Common Stock covered by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock that are covered by the Plan and which are tendered to the Company by a Participant to exercise an Award
shall be added to the number of shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the
Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of
California on the date of grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company
exceed the applicable percentage as calculated in accordance with the conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are
outstanding at the time the calculation is made.” 
 Adopted by the Board of Directors on May 10, 2013 

Adopted by the Stockholders on May 10, 2013           

  

 2007 Plan Amendment 

AMENDMENT NO. 6 TO 
 2007
STOCK INCENTIVE PLAN 
 OF 

TOKAI PHARMACEUTICALS, INC. 

The Amended and Restated 2007 Stock Incentive Plan dated April 9, 2010 (the “2007 Plan”) of Tokai Pharmaceuticals, Inc. is
hereby amended as follows: 
 Section 4 of the 2007 Plan is deleted in its entirety and the following is substituted in its place: 

“4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to 21,043,489
shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as
the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock that are covered by the Plan and which are tendered to the Company by a Participant to exercise an Award shall be added to the number of
shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the
Plan may consist in whole or in part of authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of
grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable
percentage as calculated in accordance with the conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time
the calculation is made.” 
 Adopted by the Board of Directors on February 25, 2014 

Adopted by the Stockholders on February 26, 2014           

  

 2007 Plan Amendment 

AMENDMENT NO. 7 TO 
 2007
STOCK INCENTIVE PLAN 
 OF 

TOKAI PHARMACEUTICALS, INC. 

The Amended and Restated 2007 Stock Incentive Plan dated April 9, 2010 (the “2007 Plan”) of Tokai Pharmaceuticals, Inc. is
hereby amended as follows: 
 Section 4 of the 2007 Plan is deleted in its entirety and the following is substituted in its place: 

“4. Stock Available for Awards. Subject to adjustment under Section 8, Awards may be made under the Plan for up to 22,043,489
shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”). If any Award expires or is terminated, surrendered or canceled without having been fully exercised or is forfeited in whole or in part (including as
the result of shares of Common Stock subject to such Award being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any Common Stock not being issued, the unused Common Stock covered
by such Award shall again be available for the grant of Awards under the Plan. Further, shares of Common Stock that are covered by the Plan and which are tendered to the Company by a Participant to exercise an Award shall be added to the number of
shares of Common Stock available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the
Plan may consist in whole or in part of authorized but unissued shares or treasury shares. At no time while there is any Option (as defined below) outstanding and held by a Participant who was a resident of the State of California on the date of
grant of such Option, shall the total number of shares of Common Stock issuable upon exercise of all outstanding options and the total number of shares provided for under any stock bonus or similar plan of the Company exceed the applicable
percentage as calculated in accordance with the conditions and exclusions of Section 260.140.45 of the California Code of Regulations (the “California Regulations”), based on the shares of the Company which are outstanding at the time
the calculation is made.” 
 Adopted by the Board of Directors on April 8, 2014 

Adopted by the Stockholders on April 17, 2014

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]